We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$980M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+2.41%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$242M
AUM Growth
-$107M
(-31%)
Cap. Flow
-$82.3M
Cap. Flow
% of AUM
-33.98%
Top 10 Holdings %
Top 10 Hldgs %
35.16%
Holding
111
New
21
Increased
25
Reduced
24
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRUS
Merus
MRUS
|
+$6.87M |
| 2 |
ETNB
89bio
ETNB
|
+$5.71M |
| 3 |
KALV
KalVista Pharmaceuticals
KALV
|
+$5.4M |
| 4 |
Cogent Biosciences
COGT
|
+$5.12M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$5.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$10.9M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$10.4M |
| 3 |
Immunovant
IMVT
|
+$9.22M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$5.8M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
+$5.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.87% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Stereotaxis
STXS
$126M
| – | – |
-354,925
| Closed | -$735K |
|
102
PUT
Veru
VERU
$36M
| – | – |
-17,500
| Closed | -$924K |
|
103
Wave Life Sciences
WVE
$1.09B
| – | – |
-50,000
| Closed | -$350K |
|
|
SGEN
104
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-11,016
| Closed | -$1.42M |
|
|
ISEE
105
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-88,243
| Closed | -$1.89M |
|
|
RXDX
106
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-172,400
| Closed | -$19M |
|
|
AMYT
107
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| – | – |
-192,995
| Closed | -$1.41M |
|
|
CINC
108
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| – | – |
-395,382
| Closed | -$4.86M |
|
|
MSACW
109
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
| – | – |
-49,990
| Closed | -$4.5K |
|
|
HZNP
110
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-23,054
| Closed | -$2.62M |
|
|
CTIC
111
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| – | – |
-254,361
| Closed | -$1.53M |
|
Similar funds
BIP
MVM
MFWP
FCM
KL
GFP
ADIC
PCM
Silverarc Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Silverarc Capital Management held 111 positions worth $242M, down 31% from $350M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Silverarc Capital Management withdrew a net $82.3M in Q1 2023, closing 39 positions and reducing 24 holdings. Its most notable exit was Immunovant, an estimated $9.22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 80% a quarter earlier, followed by Technology.
Against the trend, Silverarc Capital Management opened a new position in 89bio worth $6.67M.
- Silverarc Capital Management's largest Q1 2023 buy was 89bio: 438,215 shares worth $6.67M.
- Silverarc Capital Management added most to Merus in Q1 2023, an estimated $6.87M increase.
- Silverarc Capital Management's biggest Q1 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $10.9M.
- Silverarc Capital Management fully exited Immunovant in Q1 2023, selling an estimated $9.22M.
- Silverarc Capital Management's ten largest holdings make up 35% of its $242M portfolio in Q1 2023.
- Silverarc Capital Management opened 21 new positions and closed 39 in Q1 2023.
- Silverarc Capital Management's portfolio value fell 31% quarter-over-quarter to $242M.
Based on Silverarc Capital Management's 13F filing for Q1 2023, filed 15 May 2023.